LITH (BioELife) Cash-to-Debt: No Debt (1) (As of Sep. 2019)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BioELife Cash-to-Debt?

BioELife LITH -99.00% Cash-to-Debt is No Debt (1) as of Sep. 2019.

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BioELife's cash to debt ratio for the quarter that ended in Sep. 2019 was No Debt (1).

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, BioELife could pay off its debt using the cash in hand for the quarter that ended in Sep. 2019.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for BioELife's Cash-to-Debt or its related term are showing as below:

LITH's Cash-to-Debt is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.97
* Ranked among companies with meaningful Cash-to-Debt only.

BioELife  (OTCPK:LITH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

BioELife Cash-to-Debt Related Terms

BioELife Cash-to-Debt Historical Data

* Premium members only.

The historical data trend for BioELife's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

BioELife Cash-to-Debt Chart

BioELife Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.02 0.05 0.00 0.45

BioELife Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.26 0.45 0.72 No Debt No Debt

LITH vs BSPK, PCYN, CNABQ: Cash-to-Debt Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioELife's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioELife Cash-to-Debt vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioELife's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where BioELife's Cash-to-Debt falls into.


BioELife Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

BioELife's Cash to Debt Ratio for the fiscal year that ended in Dec. 2018 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=0.125 / (0.28 + 0)
=0.45

BioELife's Cash to Debt Ratio for the quarter that ended in Sep. 2019 is calculated as:

BioELife had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash-to-Debt →
What does a Cash-to-Debt of No Debt <sup>(1)</sup> mean?
BioELife (LITH) has a Cash-to-Debt of No Debt (1) as of Sep. 2019.
Is BioELife's Cash-to-Debt too high?
BioELife's current Cash-to-Debt is No Debt (1).
How does BioELife's Cash-to-Debt compare to BSPK and PCYN?
BioELife's Cash-to-Debt of No Debt (1) can be compared against companies in the Drug Manufacturers industry. The industry median Cash-to-Debt is 0.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.97, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioELife's current Cash-to-Debt is No Debt (1). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioELife stock overvalued right now?
BioELife (LITH) has a current Cash-to-Debt of No Debt (1). The current Cash-to-Debt is No Debt (1). Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For BioELife (LITH), the current Cash-to-Debt is No Debt (1) as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioELife Business Description

Address 12340 Seal Beach Boulevard, Suite B-190, Seal Beach, CA, USA, 90740
BioELife Corp is engaged in the manufacturing and distribution of Cannabinoid products. The company's product portfolio includes Combo Adult Gummies with Chirorub; Combo Tincture with Chirorub; Intensive Relief Rub; Tinctures; Adult Gummies; Premium Pre-Rolls; and Flower.